CEACAM5 and neoplasm: Here we report the results of a 89Zr-immuno-PET substudy, as part of the first-in-human phase I dose-escalation study of CEA-IL2v (NCT02004106), that investigated the biodistribution and tumor accumulation of 89Zr-CEA-IL2v in patients with CEA positive (CEA+) and CEA negative (CEA−) tumors.